Tempus AI announced the publication of its study, 'Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy,' in the Journal of Molecular Diagnostics. This study supports the utility of xF+ as a non-invasive technique for therapy selection.
Data from the study demonstrates that the xF+ assay can detect actionable variants, including resistance mutations, identify clinically relevant biomarkers, and monitor disease progression. The xF+ assay integrates with the Tempus multimodal database, supporting therapeutic recommendations and clinical research.
Originally introduced in 2022, the xF+ panel covers 523 genes and shows concordance with the Tempus xF and xT assays for MSI status and gene coverage. The validation study confirmed the assay's accuracy, sensitivity, specificity, and repeatable and reproducible precision through various clinical and control samples.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.